/PRNewswire/ - Bedford Group Transearch Life Sciences is proud to announce Rehan Verjee has joined their North American Healthcare Advisory Board. "During a.
Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare
News provided by
Share this article
Share this article
DARMSTADT, Germany, Feb. 4, 2021 /PRNewswire/ Merck KGaA, Darmstadt, Germany, which operates its Healthcare business sector as EMD Serono in the US and Canada, today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine Franchises, to pursue an opportunity outside of the Company that will soon be announced. He will be succeeded by Andrew Paterson, who is currently Senior Vice President and Head of both the Global Multiple Sclerosis (MS) Franchise and the MS business unit in the United States.
(PRNewsfoto/EMD Serono)
ROCKLAND, Mass. and NEW YORK, Jan. 25, 2021 /PRNewswire/ EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO
® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy. Avelumab is the only immunotherapy to demonstrate a significant improvement in overall survival in the first-line setting in a Phase III study in advanced or metastatic bladder cancer. With this approval by the European Commission, we can now offer patients a potential new first-line maintenance standard of care that may help them live longer, said Professor Thomas Powles, MD, Director of Barts Cancer Centre, London, UK.